Boston Medical Sciences' AIM4CRC Designated as U.S. FDA Breakthrough Device ~Accelerating Commercialization in the U.S. Market and Global Expansion with Stool-Free Virtual Colonoscopy™ AI Technology~
NQ Score
42/100
N1 Content Completeness
4
AI Summary (NQ-processed)
Boston Medical Sciences' AI-powered "stool-free virtual colonoscopy™ examination system AIM4CRC" has been designated as a Breakthrough Device by the U.S. FDA. This will reduce patient burden in colorectal cancer screening and accelerate its commercialization in the US market.